Apomorphine as subcutaneous injections offers a valuable and effective treatment alternative for Parkinson patients with oral medication-resistant "off' phases. Its efficacy is stable during long-term therapy, with no signs of patient tolerance. Adverse events are usually mild. The best results are obtained with relatively young, active, and cognitively intact patients. Intermittent s.c. apomorphine therapy can improve the patients' possibilities to continue to work and to live a normal social life, by offering increased freedom and self-confidence through a reliable, quick rescue from the disabling medication-resistant off phases.